Prescription medicine
Lapine t-lymphocyte immune globulin Brand names: Thymoglobulin
Lapine t-lymphocyte immune globulin (Thymoglobulin) is a prescription medicine. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the lapine t-lymphocyte immune globulin FDA label on DailyMed (effective June 24, 2026); every lapine t-lymphocyte immune globulin label on DailyMed.
Highlights of the record
FDA label of June 24, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageTHYMOGLOBULIN is indicated for the prophylaxis and treatment of acute rejection in adult and pediatric patients receiving a kidney transplant in conjunction with concomitant immunosuppression.
Forms and strengths
- 5 mg/ml
Injection (powder) (lyophilized) for solution.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 8,019 through July 30, 2026
What is lapine t-lymphocyte immune globulin used for?
From the label: indications and usageTHYMOGLOBULIN is indicated for the prophylaxis and treatment of acute rejection in adult and pediatric patients receiving a kidney transplant in conjunction with concomitant immunosuppression. THYMOGLOBULIN is an immunoglobulin G indicated for the prophylaxis and treatment of acute rejection in adult and pediatric patients receiving a kidney transplant in conjunction with concomitant immunosuppression.
Conditions named in the indications of lapine t-lymphocyte immune globulin's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Immunoglobulin G.
Source: FDA drug label (Thymoglobulin), Genzyme Corporation, effective June 24, 2026 (SPL set bbd8ab99-552e-4b81-aca4-6b0c7af8b9ae), via openFDA; the full label on DailyMed
Is there a generic for lapine t-lymphocyte immune globulin (Thymoglobulin)?
No generic lapine t-lymphocyte immune globulin is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do FAERS reports show for lapine t-lymphocyte immune globulin?
The FDA Adverse Event Reporting System holds 8,019 reports that list lapine t-lymphocyte immune globulin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2,038 are coded as a death and 2,960 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as lapine t-lymphocyte immune globulin?
7 other medicines are given the same way (intravenous) and in the same FDA class as lapine t-lymphocyte immune globulin or labeled mainly for the same use (organ transplant rejection), the same class first. Organ transplant rejection lists all 13 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Mycophenolate mofetil | Organ transplant rejection | 6 labelers | n/a | No current entry |
| Basiliximab | Organ transplant rejection | none listed | n/a | No current entry |
| Tacrolimus | Organ transplant rejection | 1 labeler | n/a | No current entry |
| Azathioprine | Organ transplant rejection | 1 labeler | n/a | No current entry |
| Belatacept | Organ transplant rejection | none listed | n/a | No current entry |
| Cyclosporine | Organ transplant rejection | none listed | n/a | No current entry |
| Sirolimus | Organ transplant rejection | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as lapine t-lymphocyte immune globulin
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to lapine t-lymphocyte immune globulin
- 7 medicines for the same use
- Lapine t-lymphocyte immune globulin side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other